NCT07388407Recruiting
Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis
Pharmacogenetics of Leflunomide in the RA Management
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 2 Jan 2026
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Foundation University Islamabad
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07388407
What you commit to
- Study type: Observational
- Planned participants: 110
- From 1 Sept 2024 to the primary completion date, 30 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairment, neurological disease
- Patients having inflammatory bowel disease/ Irritable bowel syndrome
- Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-
Age
- Patients below the age of 20
Other
- Patients not willing to participate/ consent not given
- Non- Pakistani origin
- Taking another DMARD simultaneously
- Compromised renal and hepatic functions
- Pregnant/ lactating patients
Who the study is looking for
- At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10
- Pakistani individuals
- between ages of 20-75 years
- New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available
Age in the registry: 20 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shifa International Hospital Coordinator of this site? Confirm its status | Islamabad | Pakistan | Completed |
| Fauji Foundation Hospital, Rawalpindi Coordinator of this site? Confirm its status | Rawalpindi | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.